DougDeSchutter and Tom Carey to take on new responsibilities Broadridge Financial Solutions, Inc. (NYSE: BR), a global Fintech leader, today announced expanded roles for two senior members of its leadership team to support Broadridge's continued evolution to a platform company. The changes are effective as of July 1. Doug DeSchutter has been named President, Investor […]
Trevi Therapeutics, Inc.(Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced that Jennifer Good, President and Chief Executive Officer, and Lisa Delfini, Chief Financial Officer, will be
— Expert dermatologist panel creates newatopic dermatitis (AD) algorithm (stepped diagnosis and treatment recommendations) emphasizing need for therapeutics that address AD's intense itch, inflammation, and the AD disease stages of Staphylococcus aureus (Staph) colonization through infection — Panel underscores unmet need for topical multi-target therapeutic such as investigational new drug candidate Zabalafin Hydrogel to meet
John Koudounis, President and CEO of Calamos, a leading alternatives manager, announced the launch of the Calamos Aksia Private Equity & Alternatives Fund (Ticker: CAPVX). The Fund is designed to provide investors with access to a diversified portfolio of private equity investments across buyouts, growth equity, and venture capital. CAPVX will focus on investing in
Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Surpasses 50% Enrollment Target GlobeNewswire July 01, 2025 PURCHASE, N.Y., July 01, 2025 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the Phase 2 'START' Study surpasses 50% enrollment.
Costamare Inc. Declares Quarterly Dividend on Its Preferred and Common Stock GlobeNewswire July 01, 2025 MONACO, July 01, 2025 (GLOBE NEWSWIRE) — Costamare Inc. (the “Company”) (NYSE: CMRE) has declared cash dividends of US $0.476563 per share on its 7.625% Series B Cumulative Redeemable Perpetual Preferred Stock (the “Series B Preferred Stock”) (NYSE: CMRE PR
Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ(R) MRD Testing into OncoEMR(R) GlobeNewswire July 01, 2025 SEATTLE, July 01, 2025 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, and Flatiron
TWL Miner Announces Advancements in AI-Powered Cloud Mining Infrastructure Following $95 Million Series B Funding TWL Miner, a UK-based cloud mining platform established in 2019, has announced the successful completion of its Series B funding round, securing $95 million to support the integration of artificial intelligence technologies into its cloud mining operations. GlobeNewswire July 01,
Abeona Therapeutics(R) Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy Abeona will receive a license payment and potential development, regulatory, and sales milestones, and royalties GlobeNewswire July 01, 2025 CLEVELAND, July 01, 2025 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Beacon Therapeutics, an ophthalmic gene
FinWise Bancorp to Host Second Quarter 2025 Earnings Conference Call and Webcast on Thursday, July 24, 2025 GlobeNewswire July 01, 2025 MURRAY, Utah, July 01, 2025 (GLOBE NEWSWIRE) — FinWise Bancorp (NASDAQ: FINW) (“FinWise” or the “Company”), the parent company of FinWise Bank, today announced that it will report its second quarter 2025 results and